Skip to main content

Genomics Essentials in Hematologic Malignancies (GENOM)

August 12, 2020

Click Here to Participate 

Foundations CME/CE Credit available until: August 31, 2022 

Applications CME/CE Credit available until: August 31, 2022

Target Audience

Hematologists, hematologists/oncologists, medical oncologists, physician assistants, nurse practitioners and nurses caring for patients with blood cancers.

Description

This series of interactive webinars will provide clinicians across the care spectrum treating hematologic malignancies with a foundational understanding of genomics, current applications and advances, and practical strategies to apply these findings to treating patients.

Foundations (15-25 minutes each)

The following cover the basics of molecular profiling and testing:

  • On Target: Terminology Matters: Getting on the Same Page (0.5 CE/CME)
  • The Toolbox: A Look at Types of Genomic Testing (0.5 CE/CME)
  • Clinical Applications: Overview of Genomic Tests & Their Use in Guiding Clinical Decisions (0.25 CE/CME)
  • Patient Points: Explaining the Importance &Implications of Testing (0.5 CE/CME)
  • On the Horizon: Key Areas of Research in Genomics of Hematologic Cancers (0.5 CE/CME)

Applications (approximately 30-60 minutes each)

The following are disease-specific, case based and explore relevant biomarkers, tests and therapies, patient communication strategies and emerging research:    

  • Adult & Pediatric Acute Lymphoblastic Leukemia (0.75 CE/CME)
  • Adult & Pediatric Acute Myeloid Leukemia & Myelodysplastic Syndromes (0.75 CE/CME)
  • Chronic Lymphocytic Leukemia (0.75 CE/1.0 CME)
  • Myeloma (0.5 CE/CME)
  • DLBCL & Aggressive T-cell Lymphomas (0.5 CE/0.75 CME)
  • Hodgkin & Non-Hodgkin Lymphomas (0.5 CE/CME)

Learning Objectives

At the conclusion of this program, participants will be able to:

  • Identify genomic principles, applications, technologies and terminology relating to biomarker development
  • Outline available genomic tests for diagnosis of hematologic malignancies and relevant premalignant conditions
  • Interpret test results and select appropriate management strategies
  • Articulate strategies to explain tests and their implications to patients and caregivers
  • Discuss ongoing genomic and genetic research in hematologic malignancies and relevant premalignant conditions

Steering Committee

Jennifer Brown, MD, PhD (Steering Committee Chair)
Director, CLL Center of the Division of Hematologic Malignancies 
Dana-Farber Cancer Institute 
Boston, Massachusetts

Anjali Advani, MD
Director, Inpatient Leukemia Unit
Taussig Cancer Institute
Cleveland, Ohio

Rafael Fonseca, MD
Director, Mayo Clinic Comprehensive Cancer Center
Phoenix, Arizona

Patricia Friend, PhD, APRN-CNS, AOCNS, AGN-BC
Associate Professor and Program Director
Marcella Niehoff School of Nursing
Loyola University Chicago
Maywood, Illinois

Neha Mehta-Shah, MD, MSCI
Assistant Professor, Department of Medicine
Washington University in St. Louis School of Medicine 
St. Louis, Missouri

Alice Mims, MD
Acute Leukemia Clinical Research Director
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio

Charles Mullighan, MBBS (Hons), MSc, MD
Deputy Director, Comprehensive Cancer Center
St. Jude Children’s Research Hospital
Memphis, Tennessee
 

Continuing Education

Physicians

The American Society of Hematology (ASH) designates the Foundations enduring activity for a maximum of 2.25 and the Applications enduring activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement: Successful completion of the Foundations  CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. The amount of points earned for the Applications CME activity are 4.25. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award up to 2.25 continuing education contact hours through the California Board of Registered Nursing for the Foundations activity. Up to 3.75 continuing education contact hours will be awarded for the Applications activity.

Nurses must attend the webinars, complete at least one hour of learning, submit the online evaluation form, and complete the online post-test to earn credit. Once submitted, the certificate will be automatically generated as a PDF online. Nurses do not have to attend all 11 modules, but should complete at least the first 5 modules on the Foundations.

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program

ILNA Categories and Points: Care Continuum 1| Diagnosis and Staging 2| Disease-Related Biology 2| Oncology Nursing Practice 1| Professional Practice 1| Roles of the APN 1| Scientific Basis  for Practice 2| |Treatment 1.5| Total Maximum = 6 ILNA Points  

Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum amount of points that can be claimed in each subject area.  The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

Providers

This activity is provided by the American Society of Hematology and The Leukemia and Lymphoma Society in collaboration with The France Foundation.

Supporters

This activity is supported by educational grants from Agios Pharmaceuticals, Inc; Astellas Pharma Inc.; Bristol Myers Squibb Company; Foundation Medicine, Inc.; Illumina, Inc.; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Servier Pharmaceuticals; and Verastem Oncology.
 

Click Here to Participate 

Participants gain access to the webinar via the registration button above.

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.



< Back to Continuing Education